What Is a CRL? When the FDA Says No to Your Biotech Stock

You own a biotech stock heading into a PDUFA date. The date arrives. Instead of an approval press release, the company files an 8-K at 6:30 AM that says “received a Complete Response Letter.” The stock opens down 50%. You are now sitting on a loss that takes a year to recover, if it ever does.

A Complete Response Letter (CRL) is the FDA’s formal way of saying it cannot approve a drug application in its current form. It explains the deficiencies and what additional data is needed. For a biotech stock, a CRL is the worst single-day outcome there is.

What a CRL is

When the FDA finishes reviewing an NDA or BLA and decides it cannot approve the drug, it sends a CRL to the sponsor. The letter lays out the specific deficiencies: manufacturing problems, insufficient efficacy data, safety concerns, or trial design issues. The company can address the deficiencies and resubmit, but that process typically takes 12 to 18 months and often longer.

Between 2018 and 2022, 37% of all BLAs and NDAs received a CRL, according to FDA user-fee data. That is more than one in three. CRLs are common, not exceptional.

The FDA publishes CRLs in a searchable table at open.fda.gov/crltable. Reading a few of them is the fastest way to internalize how the FDA communicates a rejection.

Why CRLs happen

The four most common reasons, roughly in order of frequency:

1. Manufacturing and CMC (chemistry, manufacturing, and controls). The FDA inspects the facilities where the drug will be made. If the inspection finds deficiencies in the manufacturing process, quality control, or facility compliance, the FDA issues a CRL even if the clinical data is fine. CMC rejections are the most frustrating kind because the science worked but the factory did not pass.

2. Insufficient efficacy. The drug did not show a big enough effect on the primary endpoint, or the effect size was marginal relative to the control. This is why you must read the trial data before the PDUFA. Our guide to reading a clinical trial press release shows how to spot a marginal effect size before the FDA does.

3. Safety concerns. Unexpected serious adverse events (SAEs), deaths in the drug arm above the control arm, or a safety signal that emerged during review. Safety CRLs are the hardest to fix, because the company often has to run a new trial with a lower dose or different patient population.

4. Trial design flaws. The wrong endpoint, an inadequate control arm, or a trial that was not powered enough to detect the effect. The FDA is increasingly strict about trial design in accelerated approval pathways.

What a CRL does to the stock

The typical single-day drop is 30 to 60%. Mid-cap biotechs ($500M to $5B market cap) usually drop 20 to 45%. Small caps with single-product pipelines can drop 60 to 80%, because a CRL threatens the company’s survival, not just one drug.

Real examples from 2025 to 2026:

• Sesen Bio (SESN): Stock dropped over 80% after the CRL for Vicineum in bladder cancer. The company never recovered and eventually delisted.
• Corcept Therapeutics (CORT): Stock dropped roughly 50% on December 31, 2025 after the CRL for relacorilant, a cortisol modulator.
• Capricor Therapeutics (CAPR): Stock dropped 41% on September 25, 2025 after the CRL for deramiocel in Duchenne muscular dystrophy. The FDA wanted additional registrational clinical data from the HOPE-3 trial.
• Aldeyra Therapeutics (ALDX): Stock hit a 52-week low of $1.07 on March 17, 2026, a 75% decline, after the third CRL for reproxalap in dry eye disease. Three CRLs for the same drug is a clear signal the program is effectively dead.
• Fortress Biotech (FBIO): Stock dropped 30% on October 1, 2025 after a CRL for CUTX-101 in Menkes disease, citing manufacturing compliance deficiencies at a contract facility. The science was fine; the factory failed inspection.

The recovery path is real but slow. Companies that address the deficiencies and resubmit within 12 to 18 months sometimes get approval on the second try. Replimune (REPL) is on its third BLA submission for RP1 in melanoma after CRLs in July 2025 and April 2026, with an August 2, 2026 PDUFA date. Many companies never refile. Cash burn during the fix period is the silent killer; a company that had 18 months of cash at the first PDUFA may have 6 months left by the time it resubmits.

CRL versus delay

A CRL is not the same as a PDUFA extension. When the FDA extends a PDUFA date, usually by 3 months, it is asking for more review time, often because the company submitted new data or the agency needs to process a major amendment. A delay announcement typically moves the stock down 10 to 20%, not 50%. Selling a delayed stock as if it were a CRL locks in a loss on a position that may still get approved. Our PDUFA date guide walks through the three outcomes in detail.

How to assess CRL risk before the PDUFA

The point of evaluating CRL risk is to decide before the date, not after. Four red flags:

1. Negative AdCom vote. When the FDA’s advisory committee votes against approval, the FDA follows the panel the large majority of the time. A no vote is the most reliable predictor of a CRL; the FDA concurs with negative AdCom votes roughly 85% of the time. If you own the stock and the AdCom votes no, that is your exit.

2. Manufacturing warning letters. If the FDA issued a Form 483 or warning letter to the manufacturing facility in the 12 months before the PDUFA, CMC risk is elevated. Search the company name plus “Form 483” or “warning letter” on fda.gov. Fortress Biotech’s CUTX-101 CRL is a textbook example.

3. Accelerated approval with a failed confirmatory trial. Drugs approved under accelerated approval must run a confirmatory trial to verify benefit. If the confirmatory trial fails, the FDA can withdraw the drug or reject related sBLAs. Any company living on accelerated approval data is higher risk.

4. Single-product pipeline. A biotech with one drug in the pipeline and no revenue faces an existential CRL. A biotech with three drugs in trials and one approved product can absorb a CRL. Check the pipeline before you size the position.

Common mistakes

• Holding through a negative AdCom vote. The panel vote is the signal. The PDUFA date is the formalization. If you wait for the CRL to sell, you sell 40% lower than the post-AdCom price.
• Treating a delay as a CRL. A 3-month extension is not a rejection. Panic-selling a delay turns a temporary setback into a permanent loss.
• Ignoring CMC risk. Investors focus on efficacy and forget manufacturing. A CMC CRL drops the stock just as hard as an efficacy CRL.
• Doubling down after a CRL. “It will get approved on resubmission” is a real thesis, but it requires 12 to 18 months of cash burn and no guarantee. The base rate of second-try approval is well below 50%.
• Buying the day before the PDUFA. This is the original sin of biotech investing. You are paying the run-up premium to bet on a binary outcome. Our PDUFA date guide covers why the edge is in the run-up, not the decision.

Final checklist

• Read the trial data before the PDUFA, not after the CRL
• Check for an AdCom and watch the vote
• Search for FDA manufacturing warnings on the company’s facilities
• Confirm the company has cash to survive a 12 to 18 month resubmission cycle
• Size the position for a 50% loss, because that is the base case for a CRL
• Have an exit plan written before the AdCom, not after the CRL